New pill targets tough cancers in early human trial
NCT ID NCT05490472
Summary
This early-stage study is testing a new oral drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of helping shrink tumors in cancers like certain breast cancers and small cell lung cancer. It is not designed as a cure and would likely require ongoing treatment if successful.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC ) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Jilin Cancer Hospital
RECRUITINGChangchun, Jilin, 130000, China
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
University of Utah Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.